春季カタルに対する0.1％シクロスポリン点眼液の臨床効果

Effect of 0.1％ cyclosporin ophthalmic solution for vernal keratoconjunctivitis

要約　目的：春季カタルに対する0.1％シクロスポリン点眼の効果の報告。症例と方法：春季カタル15例27眼を対象とした。男性23眼，女性4眼で，年齢は9～45歳（平均20歳），罹病期間は2か月～9年（平均3年9か月）であった。病型は13例が眼瞼型，2例が輪部型であった。13例にアトピー性皮膚炎，5例にアレルギー性鼻炎，4例に喘息があった。0.1％シクロスポリンとしてパピロック^®ミニ（参天製薬）を1日3回点眼してもらい，6か月間の経過を追った。結果：視力1.0以上の眼は，点眼開始前74％，3か月後92％，6か月後76％であった。眼圧には投与前後で変化があった。3か月後に瘙痒感が改善し，眼瞼結膜の充血と腫脹，巨大乳頭，球結膜の充血，角膜上皮障害の各項目が有意に改善した。結論：春季カタルに対する0.1％シクロスポリン点眼は有効であった。

Abstract.　Purpose：To report the outcome of instillation of 0.1％ cyclosporin for vernal keratoconjunctivitis（VKC）. Cases and Method：This prospective study was made on 27 eyes of 15 patients with VKC. The series comprised 23 male and 4 female eyes. The age ranged from 9 to 45 years, average 20 years. VKC had been present for 2 months to 9 years, average 45 months. VKC forms were seen that the tarsal form was 13 cases and the limbal form was 2 cases. Atopic dermatitis was present in 13 cases, allergic rhinitis in 5 cases, and asthma in 4 cases. Papillock^®mini, which contains 0.1％ cyclosporine, was instilled 3 times daily. Cases were followed up for 6 months. Results：Visual acuity of 1.0 or over was present in 74％ of eyes before treatment, 92％ after 3 months, and 76％ after 6 months. There was no change in intraocular pressure. Itching decreased after 3 months. Improvement was observed regarding hyperemia and swelling of palpebral conjunctiva, giant papilla, hyperemia of bulbar conjunctiva, and corneal epithelial damage. Conclusion：Instillation of 0.1％ cyclosporine was effective for VKC in the present series.